Join the club for FREE to access the whole archive and other member benefits.

Anirvan Ghosh

Chief Executive Officer at UNITY Biotechnology.

Anirvan joined UNITY as CEO in March 2020. Prior to joining UNITY, he served as senior vice president and head of research and early development at Biogen. During his tenure at Biogen, Anirvan led a team of 350 scientists and clinicians responsible for preclinical, and clinical Phase 1 and Phase 2 studies in all of Biogen’s disease areas and led a marked expansion of its early clinical portfolio. Between 2017 and 2020, ten assets advanced from Research to Development and several reported positive proof of concept studies and are now in pivotal registration-enabling clinical trials. Anirvan was also involved in expanding the portfolio through key partnerships, including acquisition of early stage assets in Alzheimer’s Disease, Schizophrenia, and Ophthalmology, and several multi-asset platform collaborations.

Visit website:



See also: Company UNITY Biotechnology - Biotechnology company devoted to research of restoring human health

Details last updated 10-Sep-2020

Anirvan Ghosh News

UNITY Biotech's lead compound lags behind the Regeneron’s eye drug

Biospace - 27-May-2023

UBX1325 showed disappointing results in phase II macular degeneration trial - further analysis is required


Data from Phase 2 BEHOLD study of UBX1325 in DME patients-Unity Biotechnology

Ophthalmology Times - 12-Aug-2022

Statistically significant treatment effect for both BCVA and CST was seen at both 12 and 18 weeks


Unity's senolytic drug reports positive phase 1 data in eye disease patients

FierceBiotech - 06-Jul-2021

Begun phase 2 trial including patients with early stage of disease to test its safety and effectiveness


Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year


Nature Biotechnology reviews the state of play of senolytics

Nature Biotechnology - 12-Nov-2020

In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...


Unity Biotechnology launches clinical trial of a new senolytic (LEAF) - 13-Oct-2020

A new approach to treat diabetic macular oedema